|
Market Closed -
Nasdaq
20:00:00 12/03/2026 GMT
|
5-day change
|
1st Jan Change
|
|
317.23 USD
|
-1.00%
|
 |
-1.02%
|
-20.22%
|
|
03-10 |
Alnylam to Webcast TTR Investor Webinar
|
BU
| |
03-05 |
Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement
|
CI
| |
03-05 |
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
|
RE
| |
03-05 |
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam
|
MT
| |
03-05 |
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics
|
RE
| |
03-05 |
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
|
AQ
| |
03-05 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,227,698, According to a Recent SEC Filing
|
MT
| |
03-03 |
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
|
RE
| |
03-02 |
Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:10 AM
| | |
03-02 |
Alnylam Pharmaceuticals receives positive recommendation from Canada's drug agency for public reimbursement of Amvuttra
|
RE
| |
03-02 |
Intellia gets FDA nod to resume second gene therapy trial after safety pause
|
RE
| |
02-23 |
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
|
BU
| |
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing
|
MT
| |
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $607,448, According to a Recent SEC Filing
|
MT
| |
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,157,542, According to a Recent SEC Filing
|
MT
| |
02-18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $695,201, According to a Recent SEC Filing
|
MT
| |
02-17 |
Analyst recommendations: Accenture, Dollar Tree, DraftKings, Moderna, Walmart…
|  | |
02-13 |
RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating
|
MT
| |
02-12 |
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
02-12 |
Alnylam Pharmaceuticals, Inc., Q4 2025 Earnings Call, Feb 12, 2026
| | |
02-12 |
Alnylam Pharmaceuticals : Q4 2025 Earnings Presentation ›
|
PU
| |
02-12 |
Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook
|
MT
| |
02-12 |
Alnylam: Q4 Earnings Snapshot
|
AQ
| |
02-12 |
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share
|
MT
| |
02-12 |
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
